The RIVER trial pre-specified analysis presented at ESC 2022 aimed to test the efficacy/safety of rivaroxaban compared to warfarin in patients with atrial fibrillation (AF) and bioprosthetic mitral valves, according to time of valve implantation. In this touchCARDIO interview, we speak with Professor Renato Lopes (Duke University Medical Center, Durham, NC, USA) to discuss non-vitamin K antagonist oral anticoagulants (NOACs), also known as direct oral anticoagulants (DOACs), in patients with AF and bioprosthetic valves as well as the RIVER trial and what questions remain unanswered that require further studies.
The abstract entitled ‘RIVER: Rivaroxaban for Valvular Heart Disease and Atrial Fibrillation’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
- What is known about the efficacy and safety of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation (AF) and bioprosthetic heart valves? (0:18)
- What do current ESC guidelines for the diagnosis and management of AF recommend in terms of NOAC usage in patients with prosthetic heart valves? (0:56)
- What were the aims, design and inclusion criteria of the RIVER trial? (1:32)
- What were the primary and secondary outcome measures and how well were they achieved? (2:32)
- What conclusions can be drawn from this study and what further studies are needed? (3:31)
Disclosures: Renato Lopes is on the advisory board for Pfizer, a consultant for Bayer, BMS, Boehringer Ingleheim, Daiichi Sankyo, GSK, Medtronic, Merck, Pfizer, Portola and Sanofi and has received grants or research support from BMS, GSK, Medtronic, Pfizer and Sanofi.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Atrial Fibrillation here
Share this Video
Related Videos In Atrial Fibrillation
Ole De Backer, TCT 2022: FEops HEARTguide™ Computational Modelling for left atrial appendage (LAA) closure, the PREDICT LAA trial
The PREDICT LAA trial aimed to examine whether cardiac computed tomography- based FEops HEARTguide™ computational modelling would benefit clinical outcomes when planning for left atrial appendage (LAA) closure. In this touchCARDIO interview, we speak with Dr Ole De Backer (Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark) to discuss the PREDICT LAA trial and the next steps. […]
Ole De Backer, TCT 2022: The use of cardiac computed tomography-based patient-specific computational simulations in left atrial appendage (LAA) closure
When performing percutaneous left atrial appendage (LAA) closure, challenges arise that impact clinical outcomes and cardiac computed tomography (CCT)- based patient-specific computational simulations provide device-host interactions. In this touchCARDIO interview, we speak with Dr Ole De Backer (Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark) to discuss these challenges and the use of cardiac computed tomography (CCT)- […]
Hugh Calkins: What can we look forward to at the Heart Rhythm Congress 2022
Prof Hugh Calkins (The Johns Hopkins University School of Medicine, Baltimore, Md, USA) explains how the Arrhythmia Alliance has been instrumental in empowering patients to become advocates for themselves, ask more questions and increase their knowledge. The Heart Rhythm Congress 2022 is back in person and a unique chance to bring patients and healthcare professionals […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!